[Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
Mellstedt
Håkan
H
Cancercentrum Karolinska, Karolinska Universitetssjukhuset Solna, Stockholm. hakan.mellstedt@karolinska.se
D000970:Antineoplastic Agents / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D001688:Biological Products / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use; D001702:Biopharmaceutics / Q000191:economics; D017046:Cost Savings; D017277:Drug Approval; D016527:Drug Costs; D004346:Drug Information Services; D016568:Drugs, Generic / Q000627:therapeutic use; D004921:Erythropoietin / Q000737:chemistry / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000737:chemistry / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use; D013678:Technology, Pharmaceutical; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001688:Biological Products; D016568:Drugs, Generic; D011994:Recombinant Proteins; D004921:Erythropoietin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007372:Interferons